1. Home
  2. Products
  3. Customized ADCs
  4. CD33
  5. Anti-CD33 (clone hP67.6)-AcBut-Calicheamicin ADC

Anti-CD33 (clone hP67.6)-AcBut-Calicheamicin ADC (CAT#: ADC-W-464)

This ADC product is comprised of an Anti-CD33 antibody (clone hP67.6) conjugated via a AcBut linker to Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • hP676
  • Similar to
  • gemtuzumab ozogamicin
  • Name
  • CD33
  • Alternative Names
  • CD33; CD33 molecule; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3;
  • Target Entrez Gene ID
  • 945
  • Overview
  • CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
  • Overview
  • Anti-CD33 lgG4κ Antibody, clone # hP676
  • Generic name
  • gemtuzumab
  • Clone #
  • hP676
  • Species Reactivity
  • Human
  • Name
  • AcBut (4-(4-acetylphenoxy)butanoic acid)
  • Description
  • Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
  • Name
  • Calicheamicin
  • Description
  • Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-464. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-492 Anti-CD33 (h2H12ec)-Mc-VC-SGD-1882 ADC mc-VC (maleimidocaproyl-valine-alanine) SGD-1882
ADC-W-817 Anti-CD33 (Lintuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-115 Anti-CD33 (clone h2H12)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2537 Anti-CD33 (Gemtuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2538 Anti-CD33 (Gemtuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-461 Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC AcBut (4-(4-acetylphenoxy)butanoic acid) CalichDMH
CAT# Product Name Linker Payload
ADC-W-008 Anti-TPBG (clone A1)-AcBut-calicheamicin ADC  AcBut [-(4' acetyl phenoxy) butanoic acid] calicheamicin
ADC-W-556 Anti-EphA4-calicheamicin ADC Calicheamicin
WJY-0423-LS106 Protein A-Calicheamicin ADC Cleavable linkers Calicheamicin
ADC-W-357 Anti-CD33 (clone HuM195)-AcBut-Calicheamicin ADC  AcBut [-(4' acetyl phenoxy) butanoic acid] calicheamicin
ADC-W-338 Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC hydrazone calicheamicin

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.